Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...
Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid ...
Stocktwits on MSN
SLS stock jumps overnight after new investor disclosure – retail flags ‘massive’ options bet ahead of AML data
CEO Angelos Stergiou said slower event accrual may signal a “highly effective active arm.” ...
A 1,563‑sample chromatin atlas reveals 16 epigenomic subgroups of AML, redefining disease classification, prognosis, and therapeutic vulnerabilities.
Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results